Metformin pharmacogenomics: Current status and future directions

Diabetes

Volumn 63, Issue 8, 2014, Pages 2590-2599

  Pawlyk, Aaron C ^a   Giacomini, Kathleen M ^b   McKeon, Catherine ^a   Shuldiner, Alan R ^c   Florez, Jose C ^d,e  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PHARMACOGENETICS;

EID: 84905019074     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1367     Document Type: Review

References (58)

1. Holman R. Metformin as first choice in oral diabetes treatment: the UKPDS experience. Journ Annu Diabetol Hotel Dieu 2007:13-20
2. Nathan DM, Buse JB, Davidson M.B., et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hypergly-cemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193-203
3. Inzucchi SE, Bergenstal RM, Buse J.B., et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35:1364-1379
4. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37(Suppl. 1):S14-S80
5. The Diabetes Prevention Program Research Group. Ten-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374:1677-1686
6. Knowler WC, Fowler WC, Hamman R.F., et al.; Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012; 35:731-737
7. Hermann LS. Biguanides and sulfonylureas as combination therapy in NIDDM. Diabetes Care 1990; 13(Suppl. 3):37-41
8. Bailey CJ, Turner RC Metformin. N Engl J Med 1996; 334:574-579
9. Kahn SE, Haffner SM, Heise M.A., et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-2443
10. Cook MN, Girman CJ, Stein P.P., Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care. Diabet Med 2007; 24:350-358
11. U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44:1249-1258
12. Gong L, Goswami S, Giacomini K.M., Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 2012; 22:820-827
13. Garber AJ, Duncan TG, Goodman A.M., Mills DJ, Rohlf JL. Efficacy of met-formin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103:491-497
14. Turner RC. The U.K. Prospective Diabetes Study. A review. Diabetes Care 1998; 21(Suppl. 3):C35-C38
15. Rodbard HW, Jellinger PS, Davidson J.A., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15:540-559
16. Zolk O. Disposition of metformin: variability due to polymorphisms of organic cation transporters. Ann Med 2012; 44:119-129
17. Foretz M, Hébrard S, Leclerc J., et al. Metformin inhibits hepatic gluco-neogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010; 120:2355-2369
18. Jablonski KA, McAteer JB, de Bakker PI, et al.; Diabetes Prevention Program Research Group. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 2010; 59:2672-2681
19. Miller RA, Chu Q, Xie J., Foretz M, Viollet B, Birnbaum MJ Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013; 494:256-260
20. Chen L, Pawlikowski B, Schlessinger A., et al. Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics 2010; 20:687-699
21. Haffner S, Temprosa M, Crandall J., et al.; Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54: 1566-1572
22. Anfossi G, Russo I, Bonomo K., Trovati M. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol 2010; 8:327-337
23. Mithieux G, Rajas F, Zitoun C. Glucose utilization is suppressed in the gut of insulin-resistant high fat-fed rats and is restored by metformin. Biochem Pharmacol 2006; 72:1757-1762
24. Schiller JS, Lucas JW, Ward B.W., Peregoy JA: Summary health statistics for U. S. adults: National Health Interview Survey, 2010. Vital Health Stat 10; 2012:1-207
25. Santoro N. Childhood obesity and type 2 diabetes: the frightening epidemic. World J Pediatr 2013; 9:101-102
26. Zeitler P, Hirst K, Pyle L., et al.; TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012; 366:2247-2256
27. Morris AD, Boyle DI, MacAlpine R, et al; DARTS/MEMO Collaboration. The Diabetes Audit and Research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. BMJ 1997; 315:524-528
28. Rena G, Pearson ER, Sakamoto K. Molecular action and pharmacogenetics of metformin: current understanding of an old drug. Diabetes Management 2012; 2:439-452
29. Zhou K, Bellenguez C, Spencer C.C., et al.; GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2; MAGIC Investigators. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011; 43:117-120
30. van Leeuwen N., Nijpels G, Becker M.L., et al. A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia 2012; 55:1971-1977
31. Tkác I. Replication of the association of gene variant near ATM and response to metformin. Pharmacogenomics 2012; 13:1331-1332
32. Yee SW, Chen L, Giacomini KM The role of ATM in response to metformin treatment and activation of AMPK. Nat Genet 2012; 44:359-360
33. Woods A, Leiper JM, Carling D. The role of ATM in response to metformin treatment and activation of AMPK. Nat Genet 2012; 44:360-361
34. Knowler WC, Barrett-Connor E, Fowler S.E., et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403
35. Crandall J, Schade D, Ma Y., et al.; Diabetes Prevention Program Research Group. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci 2006; 61:1075-1081
36. The Diabetes Prevention Program Research Group. Relationship of body size and shape to the development of diabetes in the Diabetes Prevention Program. Obesity (Silver Spring) 2006; 14:2107-2117
37. Ratner RE, Christophi CA, Metzger B.E., et al.; Diabetes Prevention Program Research Group. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 2008; 93:4774-4779
38. Ratner R, Goldberg R, Haffner S., et al.; Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005; 28:888-894
39. Florez JC, Jablonski KA, Taylor A, et al; Diabetes Prevention Program Research Group. The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. Diabetes Care 2012; 35: 1864-1867
40. Shu Y, Sheardown SA, Brown C, et al Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422-1431
41. Shu Y, Brown C, Castro R.A., et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008; 83:273-280
42. Stocker SL, Morrissey KM, Yee S.W., et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther 2013; 93:186-194
43. Choi JH, Yee SW, Ramirez A.H., et al. A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther 2011; 90: 674-684
44. Relling MV, Gardner EE, Sandborn W.J., et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011; 89:387-391
45. Gottesman O, Kuivaniemi H, Tromp G., et al.; eMERGE Network. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med 2013; 15:761-771
46. Topol EJ. Pharmacy benefit managers, pharmacies, and pharmacogenomic testing: prescription for progress? Sci Transl Med 2010; 2:44cm22
47. Charland SL, Agatep BC, Herrera V, et al Providing patients with phar-macogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial. Pharmacogenomics J 2014; 14:272-280
48. Haga SB, LaPointe NM The potential impact of pharmacogenetic testing on medication adherence. Pharmacogenomics J 2013; 13:481-483
49. Stanek EJ, Sanders CL, Taber K.A., et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther 2012; 91:450-458
50. Relling MV, Klein TE CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011; 89:464-467
51. Shuldiner AR, Relling MV, Peterson J.F., et al.; Pharmacogenomics Research Network Translational Pharmacogenetics Program Group. The Pharmacoge-nomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther 2013; 94:207-210
52. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009; 9:242-247
53. Christensen MM, Brasch-Andersen C, Green H., et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and gly-cosylated hemoglobin A1c. Pharmacogenet Genomics 2011; 21:837-850
54. Gambineri A, Tomassoni F, Gasparini D.I., et al. Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2010; 95:E204-E208
55. Shikata E, Yamamoto R, Takane H., et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 2007; 52:117-122
56. Tzvetkov MV, Vormfelde SV, Balen D, et al The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009; 86:299-306
57. Dong M, Gong ZC, Dai X.P., et al. Serine racemase rs391300 G/A polymorphism influences the therapeutic efficacy of metformin in Chinese patients with diabetes mellitus type 2. Clin Exp Pharmacol Physiol 2011; 38:824-829
58. Legro RS. Impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women: do we need a new drug? J Clin Endocrinol Metab 2008; 93:4218-4220